Non-pandemic Influenza JCG0328v2
The Joint Trust Guideline for: The antiviral drugs oseltamivir and zanamivir are used for the treatment and prophylaxis of influenza. In the event of an influenza outbreak it is imperative that action is taken quickly in order to reduce transmission and to keep the number of cases to a minimum thereby reducing the burden on the hospital and staff in terms of sickness. Oseltamivir and zanamivir are effective in reducing symptoms duration of symptoms and improving return to normal activity reducing the requirement for antibiotics and hospitalisation and reducing the probability of dying.
This guideline applies to the management of the currently seasons 2012/2013 circulating influenza viruses which include:
1 Influenza A H1N1 pdm09
2 Influenza A H3N2
3 Influenza B.
Clinical GuidelinesThis guideline has been approved by the Trust's Clinical Guidelines Assessment Panel as an aid to the diagnosis and management of relevant patients and clinical circumstances. Not every patient or situation fits neatly into a standard guideline scenario and the guideline must be interpreted and applied in practice in the light of prevailing clinical circumstances, the diagnostic and treatment options available and the professional judgement, knowledge and expertise of relevant clinicians. It is advised that the rationale for any departure from relevant guidance should be documented in the patient's case notes.
The Trust's guidelines are made publicly available as part of the collective endeavour to continuously improve the quality of healthcare through sharing medical experience and knowledge. The Trust accepts no responsibility for any misunderstanding or misapplication of this document.